Imaging of cervical cancer

Imaging

Volumn 18, Issue 1, 2006, Pages 10-19

  Lopez C ^a   Chakravarti, S ^b  

^a BIRMINGHAM WOMEN S HOSPITAL   (United Kingdom)

^b DEPARTMENT OF OBSTETRICS AND GYNAECOLOGY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CONTRAST MEDIUM; FLUORODEOXYGLUCOSE F 18; GLUCAGON; ORAL CONTRACEPTIVE AGENT; SCOPOLAMINE BUTYL BROMIDE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

ARTICLE; BRACHYTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; COST EFFECTIVENESS ANALYSIS; CYSTOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DISEASE COURSE; DRUG COST; ECHOGRAPHY; EXTERNAL BEAM RADIOTHERAPY; HISTOPATHOLOGY; HUMAN; HYSTERECTOMY; INTERMETHOD COMPARISON; INTRAVENOUS UROGRAPHY; LYMPH NODE METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SIGMOIDOSCOPY; TUMOR VOLUME; UTERINE CERVIX BIOPSY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; UTERUS SURGERY; VIRUS CARCINOGENESIS; WART VIRUS;

EID: 44649198303     PISSN: 09656812     EISSN: None     Source Type: Journal    
DOI: 10.1259/imaging/51367509     Document Type: Article

References (39)

1. Greenlee RT, Murray T, Bolden S, et al. Cancer statistics 2000. Cancer J Clin 2000;50:7-33.
2. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001;2:533-43.
3. Sasieni P, Adams J. Effect of screening on cervical cancer mortality in England and Wales: analysis of trends with an age period cohort model. BMJ 1999;318:1244-5.
4. Quinn M, Babb P, Jones J, et al. Effect of screening on incidence and mortality from cancer of the cervix in England: evaluation based routinely on collected statistics. BMJ 1999;318:904-8.
5. Parkin DM, Whelan SL, editors. Patterns of cancer in five continents. Lyon: International Agency for Research on Cancer Scientific Publications, 1990.
6. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-9.
7. Luesley D, Leeson S. Colposcopy and programme management. Guidelines for the NHS Cervical Screening Programme; NHSCSP Publication No. 20: April 2004.
8. Shaw RW, Soutter PW, Stanton SL. Gynaecology, 2nd edn. Edinburgh: Churchill Livingstone; 1997.
9. Shepherd JH. Staging Announcement. FIGO staging of gynaecological cancers: cervical and vulval [erratum in Int J Gynecol Cancer 1995;5:465]. Int J Gynecol Cancer 1995;5:319.
10. Hawnaur J. Uterine and cervical tumours. Imaging in oncology, 2nd edn. Abingdon: Taylor & Francis: 2004.
11. Abu JI, Nunns D, Davies Q et al. The current management of cervical cancer. Review. The Obstetrician and Gynaecologist 2004;196-202.
12. Sheu M, Chang CY, Wang JH, Yen MS. Preoperative staging of cervical carcinoma with MR Imaging: a reappraisal of diagnostic accuracy and pitfalls. Eur Radiol 2001;11:1828-33.
13. Hricak H, Powell CB, Yu KK, et al. Invasive cervical carcinoma: role of MR imaging in pre-treatment work-up, cost minimization and diagnostic efficacy analysis. Radiology 1996;198:403-9.
14. Sironi S, De Cobelli F, Scarfone G, et al. Carcinoma of the cervix: value of plain and gadolinium-enhanced MR imaging in as sessing degree of invasiveness. Radiology 1993;188:797-801.
15. Scheidler J, Heuck AF, Steinborn M, et al. Parametrial invasion in cervical carcinoma: evaluation of detection at MR imaging with fat suppression. Radiology 1998;206: 125-9.
16. Hricak H, Hamm B, Semelka RC, et al. Carcinoma of the uterus: use of gadopentate dimeglumine in MR imaging. Radiology 1991;181:95-106.
17. Yamashita Y, Baba T, Nishimura R, et al. Dynamic contrast-enhanced MR Imaging of uterine cervical cancer: pharma-cokinetic analysis with histopathologic correlation and its importance in predicting the outcome of radiation therapy. Radiology 2000,216:803-9.
18. Yamashita Y, Takahashi M, Sawada T, et al. Carcinoma of the cervix: dynamic MR imaging. Radiology 1992;182:643-8.
19. Seki H, Azumi R, Kimura M, et al. Stromal invasion by carcinoma of the cervix: assessment with dynamic MR imaging. AJR Am J Roentgenol 1997;168:1579-85.
20. Shiraiwa M, Joja I, Asakawa T, et al. Cervical carcinoma: efficacy of thin-section oblique axial T2-weighted images for evaluating parametrial invasion. Abdom Imaging 1999;24:914-9.
21. Husband JES, Johnson RJ, Reznek RH. A guide to the practical use of MRI in Oncology. RCR, 1999.
22. Peppercorn. PD, Jeyarajah AR, Woolas R, et al. Role of MR imaging in the selection of patients with early cervical carcinoma for fertility-preserving surgery: initial experience. Radiology 1999;212:395-9.
23. Akata D, Kerimoglu. U, Hazirolan T, et al. Efficacy of transvaginal contrast-enhanced MRI in the early staging of cervical carcinoma. Eur Radiol 2005;15:1727-33.
24. Wagenaar HC, Trimbos JB, Postema S, et al. Tumour diameter and volume assessed by magnetic resonance imaging in the prediction of outcome for invasive cervical cancer. Gynecol Oncol 2001;82:474-82.
25. Hricak H, Quivey JM, Campos Z, et al. Carcinoma of the cervix: predictive value of clinical and magnetic resonance (MR) imaging assessment of prognostic factors. Int J Radiat Oncol Biol Phys 1993;27:791-801.
26. Follen M, Levenback CF, Iyer RB, et al. Imaging in cervical cancer. Cancer 2003;98:2028-38.
27. Drescher CW, Hopkins MP, Roberts JA. Comparison of the pattern of metastatic spread of squamous cell cancer and adenocarcinoma of the uterine cervix. Gynecol Oncol 1989;33:340-3.
28. Yang WT, Lam WWM, Yu MY, et al. Comparison of dynamic helical CT and dynamic MR imaging in the evaluation of pelvic nodes in cervical cancer. AJR Am J Roentgenol 2000;175:759-66.
29. Havrilesky LJ, Kulasingam SL, Matchar DB, et al. FDG-PET for management of cervical and ovarian cancer. Gynecol Oncol 2005;97:183-91.
30. Pannu HK, Wang KP, Borman TL, et al. MR imaging of mediastinal lymph nodes: evaluation using a superparamagnetic contrast agent. J Magn Reson Imaging 2000;12:899-904.
31. Mack MG, Balzer JO, Straub R, et al. Superparamagnetic iron oxide-enhanced MR imaging of head and neck lymph nodes. Radiology 2002;222:239-44.
32. Michel SC, Keller TM, Frohlich JM, et al. Preoperative breast cancer staging: MR imaging of the axilla with ultrasmall superpararnagnetic iron oxide enhancement. Radiology 2002;225:527-36.
33. Fulcher AS, O'Sullivan SG, Segreti EM, et al. Recurrent cervical, carcinoma: typical and atypical manifestations. Radiographics 1999;19:S103-16.
34. Subak LL, Hricak H, Powell CB, et al. Cervical carcinoma: computed tomography and magnetic resonance imaging for preoperative staging. Obstet Gynecol 1995;86:43-50.
35. Hacker NF. Cervical cancer. Practical gynaecologic oncology. Philadelphia, PA: Lippincott, Williams & Wilkins, 2004:345-405.
36. Laridoni F, Maneo A, Colombo A, et al. Randomized study of radical surgery versus radiotherapy for stage Ib-lla cervical cancer. Lancet 1997;350:535-40.
37. Hreshchyshyn MM, Aron BS, Boronow RC, et al. Hydroxyurea or placebo combined with radiation to treat stages IIb and IV cervical canter confined to the pelvis. Int J Radiat Oncol Biol Phys 1979;3:317-22.
38. Cochran AJ. Surgical pathology remains pivotal in the evaluation of 'sentinel' lymph nodes. Am J Surg Pathol 1999;23:1169-72.
39. Dargent D, Martin X, Mathevet P. Laparoscopic assessment of sentinel lymph node in early stage cervical cancer. Gynecol Oncol 2000;79:411-5.